Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year High – Should You Buy?

Roivant Sciences Ltd. (NASDAQ:ROIV)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $23.57 and last traded at $23.3630, with a volume of 5344326 shares. The stock had previously closed at $22.16.

Analysts Set New Price Targets

A number of brokerages have issued reports on ROIV. JPMorgan Chase & Co. raised their price objective on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, September 18th. Guggenheim reissued a “buy” rating and issued a $28.00 price target on shares of Roivant Sciences in a research note on Thursday, December 18th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. The Goldman Sachs Group lifted their price objective on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Citigroup increased their target price on Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.19.

Roivant Sciences Stock Performance

The firm has a market cap of $16.30 billion, a P/E ratio of -41.86 and a beta of 1.22. The stock’s 50-day moving average is $21.26 and its 200 day moving average is $16.32.

Insider Activity at Roivant Sciences

In other news, major shareholder Vivek Ramaswamy sold 353,745 shares of Roivant Sciences stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $22.05, for a total transaction of $7,800,077.25. Following the transaction, the insider owned 34,132,463 shares in the company, valued at $752,620,809.15. The trade was a 1.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel Allen Gold sold 777,332 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $23.07, for a total value of $17,933,049.24. Following the completion of the transaction, the director owned 16,353,113 shares of the company’s stock, valued at $377,266,316.91. This represents a 4.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 12,983,775 shares of company stock valued at $276,477,147 over the last 90 days. Insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Large investors have recently made changes to their positions in the stock. Bessemer Group Inc. lifted its position in Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. Allworth Financial LP raised its stake in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the period. Utah Retirement Systems raised its stake in shares of Roivant Sciences by 3.0% in the 3rd quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock valued at $312,000 after purchasing an additional 600 shares during the period. Xponance Inc. lifted its holdings in shares of Roivant Sciences by 1.9% in the third quarter. Xponance Inc. now owns 46,718 shares of the company’s stock valued at $707,000 after purchasing an additional 882 shares in the last quarter. Finally, CWM LLC boosted its position in shares of Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after buying an additional 920 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.